4D Molecular Therapeutics, Inc. announced effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the board of directors (the board) of the company as chief scientific officer of the company. On January 1, 2024, Dr. Kasahara delivered notice of his resignation from the board of the company, including his role as a member and the chair of the science and technology committee of the board, effective on January 1, 2024. Dr. Kasahara?s resignation from the board is not a result of a disagreement with the company or the board on any matter relating to the company?s operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.25 USD | -1.19% | -7.92% | +14.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.76% | 1.19B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FDMT Stock
- News 4D Molecular Therapeutics, Inc.
- 4D Molecular Therapeutics, Inc. Announces Management Changes